Awards & Grants

2022 CSCC Award Winners

Outstanding Contribution to Clinical Chemistry

Ronald A. Booth

Presented as a mark of recognition of outstanding achievement in and/or contribution to the field of clinical chemistry

Sponsored by:

Dr. Ronald Booth, BSc, MSc, PhD, FCACB, FAACC is the recipient of the 2022 CSCC Award for Outstanding Contributions to Clinical Chemistry.

Dr. Ronald Booth is a Clinical Biochemist in the Division of Biochemistry with the Department of Pathology and Laboratory Medicine, The Ottawa Hospital and the Eastern Ontario Regional Laboratory Association (E ORLA). Dr. Booth directs the Immunology and Neurobiomarkers Section of the EORLA regional laboratory and is an Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Ottawa. He is also the Medical Laboratory Director and/or Clinical Biochemistry consultant for various community hospitals in the Eastern Ontario region.

Dr Booth has been a member of various Clinical Biochemistry National and International committees over the years including, International Federation of Clinical Chemistry (IFCC) Harmonisation of Interpretive Comments EQA (WG-ICQA), the Sub-group for harmonisation of reporting of protein electrophoresis and serum free light chains and quantification of small monoclonal proteins. He is the founder and chair of the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group (MGWG) and chair of the Canadian Society of Clinical Chemists Monoclonal Gammopathy Interest Group (MGIG). Dr. Booth is on the Executive Committee of the Autoantibody Network and has served as an Expert Member of the Health Technology Expert Review Panel (HTERP) with The Canadian Agency for Drugs and Technologies in Health (CADTH).

Dr. Booth sits on the Institute for Quality Management in Healthcare (IQMH) Endocrinology & Immunology Committee having served on the committee for 13 years as a member, vice-chair, and now current chair.

Dr Booth has been active in both the Ontario Society of Clinical Chemists (OSCC) and the Canadian Society of Clinical Chemists (CSCC). From 2007 to 2021 he served as Councilor, President-Elect, President and PastPresident of the OSCC and from 2008 to 2014 as Treasurer of the CSCC. During his term of office as CSCC Treasurer, Ron gathered all of the CSCC investments, which were spread among various banks and investment houses, and consolidated everything in one place. This allowed for more effective tracking, proper diversification, and streamlined record keeping of the CSCC assets.

Dr. Booth is also an active teacher and researcher. He is the course coordinator of an undergraduate course on Pathological Chemistry and is involved in training residents. Dr Booth’s Clinical research interests include diagnostic immunology and autoimmunity, neurobiomarkers and evidence-based utilization of clinical laboratory biomarkers.

Dr. Booth is Associate Editor on the Clinical Biochemistry Journal Editorial Board and reviewer for American Heart Journal, Clinical Pharmacology & Therapeutics, Canadian Medical Association Journal, Critical Reviews in Laboratory Science, Journal of Rheumatology, Annals of Clinical Biochemistry, Archives of Pathology and Laboratory Medicine and Journal of Applied Laboratory Medicine.

Dr. Booth was the 2009 Recipient of the Daniel J Campbell Award for Excellence in Clinical Biochemistry.

See Less

2021

Stephen Hill

2020

Edgard Delvin

2019

SM Hossein Sadrzadeh

2018

Nathalie Lepage

2017

Edward Randell

2016

Jawahar (Jay) Kalra

2015

Trefor Higgins

2014

Eleftherios Diamandis

2013

Raymond Lepage

2012

Andrew R. MacRae

2011

Sherry L. Perkins

2010

David Kinniburgh

2009

Connie Prosser

2008

Elizabeth Hooper

2007

Kent C. Dooley

2006

Khosrow Adeli

2005

Edward Young

2004

Bhushan Kapur

2003

James Wesenberg

2002

Randall W. Yatscoff

2001

Lynn Allen

2000

Albert D. Fraser

1999

Robert W. Moore

1998

David W. Seccombe

1997

John Krahn

1996

Jean-Claude Forest

1995

A.W. Luxton

1994

Regis Duffy

1993

Maurice Bernstein (awarded posthumously)

1992

Raymond R. Ogilvie

1991

David M. Goldberg

1990

Cliff K. Harris

1989

Guy Letellier

1988

Roger J. Thibert

1987

Chris W. Walker

1986

Paul Desjardins

1985

Matthew J. McQueen

1984

C. Cousins

1983

M. Francoeur (awarded posthumously)

1982

J. Gilbert Hill

1981

J.E. Logan

1980

A.G. Stewart

1979

Leebert A. Wright

1978

Arlene Crowe

1977

Allan G. Gornall

1976

M.W. Weatherburn

1975

Samuel W. Levy

1974

John C. Nixon

1973

Reuben Schucher

1972

R.H. Pearce

1971

C.J. Porter

1970

D.J. Campbell

1969

S.H. Jackson

1968

David B. Tonks (1st winner)

1. The Award shall be presented as a mark of recognition of outstanding achievement in and/or contribution to the field of clinical chemistry.

2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.

3. Siemens has agreed to make an annual contribution of $3,000 CDN to sponsor this award. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.

4. The Awards Committee shall choose the recipient of the Award.

5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.

6. The President of the Society will notify the recipient(s) of the award and inform Siemens Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made. 7. The recipient of the Award is not usually expected to give an address or give a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society. A representative of Siemens shall be invited to participate in the presentation.

8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.

9. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award. Council of the Society and the corporate sponsor of this award should review these terms of reference a minimum of once every 5 years.

Innovation in Laboratory Medicine

CSCC Point-of-Care Testing (POCT) Special Interest Group.

Presented to a clinical laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of clinical chemistry, pathology or laboratory medicine.

Sponsored by:

The CSCC is pleased to award the 2022 Award for Innovation in Laboratory Medicine, sponsored by Roche Diagnostics, to the CSCC Point-of-Care Testing (POCT) Special Interest Group.

The point of care testing (POCT) special interest group (SIG) of the CSCC was first established in 2014. The special interest group is made up of many dedicated members and because of their committed efforts, the group was able to publish a position statement on POCT on behalf of the CSCC in 2018 [1]. Following this publication, the group began work on a guidance document on quality assurance practices for POCT. This was published in 2021 [2] and serves as an important resource for the oversight of POCT.

A sub-group of POCT SIG members, under the leadership of Dr. Angela Fung, has been formed to address concerns and provide recommendations for intrapartum fetal scalp lactate testing. This group has been successful in publishing recommendations in the Journal of Obstetrics and Gynaecology of Canada [3].

The POCT SIG is currently collaborating with the CSCC Quality Indicator SIG to develop and track quality indicators for POCT, with the aim of providing consensus guidance on quality indicators for POCT. Another collaborative project between the CSCC, AACC critical and POCT Division and American Diabetes Association is being led by the POCT SIG. This project is aimed at developing consensus guidelines for the use of continuous glucose monitors in hospitalized patients.

Thank you to all members of the POCT SIG, past and present, who have contributed to these initiatives. Paul Yip Michael Knauer Allison Venner Angela Fung Jennifer Shea James Dalton Anna Fuezery Mathieu Provencal Yun Huang Lyne Massicotte Lori Beach Nicolas Tetreault Julie Shaw, Chair POCT SIG

References: 1. Yip PM, Venner AA, Shea J, Fuezery A, Huang Y, Massicotte L, Tetreault N, Tomalty C and Shaw JLV. Point-of-care testing: A position statement from the Canadian Society of Clinical Chemists. Clinical Biochemistry. 2018;53:156-159. 2. Venner AA, Beach LA, Shea JL, Knauer MJ, Huang Y, Fung AWS, Dalton J, Provencal M and Shaw JLV. Quality assurance practices for point of care testing programs: Recommendations by the Canadian society of clinical chemists point of care testing interest group. Clinical Biochemistry. 2021;88:11-17. 3. Fung AWS, Mattman A, Wang L, Burton T, Beach LA, Fuezery AK, CSCC Point of Care Testing Interest group. Intrapartum Fetal Scalp Lactate Testing: Considerations for Implementation and Clinical Decision Making. Journal of Obstetrics and Gynaecology of Canada. 2021;43(11):1244-1246.

See Less

2021 Kidney Check Program - University of Manitoba and Chronic Disease Innovation Centre at Seven Oaks General Hospital (Dr. Paul Komenda), in collaboration with the Shared Health Diagnostics Services (Dr. AbdulRazaq Sokoro), and the First Nations Social Service Secretariat Manitoba (Dr. Barry Lavallee)University of Manitoba and Chronic Disease Innovation Centre at Seven Oaks General Hospital (Dr. Paul Komenda), in collaboration with the Shared Health Diagnostics Services (Dr. AbdulRazaq Sokoro), and the First Nations Social Service Secretariat Manitoba (Dr. Barry Lavallee)
2020 Choosing Wisely Campaign in Laboratory Medicine at St. Michael's Hsopital Toronto
2019 Toxicology Network of Alberta Health Services
2018 Calgary Laboratory Services
Transformation of urine drug testing to meet the clinical demands for addiction services and emergency services
2017 University Health Network
Development and implementation of a shot-gun proteomics-based amyloidosis subtyping assay by Mass Spectrometry
2016 Juravinski Cancer Centre, Hamilton ON
Project on Cardiac Troponin Measurements in the Non-cardiac Surgical Population
2015 CALIPER Project
Clinical Biochemistry Division, Hospital for Sick Kids (1st winner)

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.

2. Eligible organizations for this award include:

2.1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.

2.2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.

3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:

3.1. Innovation in strategic planning and implementation of laboratory services based on best practices.

3.2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).

3.3. Innovation in teaching and education.

3.4. Promotion of a positive public image for laboratory medicine.

4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:

4.1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.

4.2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.

4.3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).

5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.

6. Nominations for this award shall be solicited annually in the Newsletter of the Society.

7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.

8. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (plaque and display item) at the CSCC Annual Meeting banquet. The award will be presented by a representative from Roche Diagnostics.

The award will cover airfare, accommodations and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. Photographs and a brief summary of the award will be provided to the hospital or institution for their publication.

9. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.

10. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.

11. The President of the Society will notify the recipient organization of the Award, and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.

12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.

13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five year.

Innovation in Laboratory Medicine

Type of Organization (Check as many as apply)(Required)
Outstanding accomplishment criteria met by this initiative/project:(Required)

References

Applications must be completed by CSCC members:
Name of CSCC Member(Required)
Nominating member: (CSCC member completing application form providing letter of nomination)
In Nominated Organization
Address(Required)
Name of Administrator:
Member of organizations administrative team providing letter of reference
In Nominated Organization
Address(Required)
Confirmation(Required)

Research Excellence

Mari L. DeMarco

Presented to an individual or group, as a mark of recognition of their contribution to research directly or indirectly related to clinical chemistry in Canada.

Sponsored by:

The CSCC is pleased to award the 2022 award for Research Excellence sponsored by Ortho Clinical Diagnostics to Dr. Mari L. DeMarco

Mari DeMarco, PhD, DABCC, FAACC, FCACB, is a Clinical Chemist at Providence Health Care, the Research Director of Providence Research, and a Clinical Associate Professor in Pathology and Laboratory Medicine at the University of British Columbia in Vancouver Canada. Dr. DeMarco completed her PhD in the Biomolecular Structure and Design program at the University of Washington, and a clinical chemistry fellowship at Washington University School of Medicine.

As a Clinical Chemist, Dr. DeMarco has input into all aspects of the clinical chemistry laboratory and is a major voice in all clinical chemistry test decision making whether the testing pertains to routine chemistry, immunoassay, electrophoresis, or mass spectrometry. She takes responsibility for determining the need for new testing and its implementation, interpretation, and quality monitoring.

Dr DeMarco’s strong research interest is in bridging protein biochemistry and analytical chemistry her research group focuses on building new biofluid tests for direct translation into patient care (www.DeMarcoLab.ca). Biomarker projects in the DeMarco group are driven by clinical demand, that is, they work collaboratively with health care providers and patients to build biofluid diagnostics to fill unmet needs in medicine. While the group uses a variety of techniques to solve biomarker-related challenges in medicine, their specialty is clinical mass spectrometry.

Important contributions of her research group include streamlining proteomic workflows to enable implementation by clinical labs. A major obstacle to the uptake of mass spec workflows for quantification of peptide and protein biomarkers in a clinical setting had been the laborious and lengthy sample preparation protocols. The DeMarco group’s early contributions re-evaluated the status quo for clinical proteomics workflows, yielding simple and rapid workflows suitable for use in clinical lab environments. The knowledge gained through this work enable important contributions to the first Clinical and Laboratory Standards Institute guideline on quantitative protein mass spectrometry; guidelines which are used by the regulatory agencies in the approval process for new in vitro diagnostic tests.

A particular area of interest for her research group is in advancing protein-based clinical diagnostics for neurodegenerative disorders, such as Alzheimer’s disease, frontotemporal dementia and Lewy body dementia. The goal of this program of research is to ensure that new biomarker tools make the challenging jump from research into healthcare. As an example, Dr. DeMarco is the Principal Investigator of a Canadawide study investigating the impact of Alzheimer’s disease biomarkers in routine care (www.impactAD.org) – a major outcome of which was the launch of the national Alzheimer’s disease biomarker testing program which provides access to medical testing for the core Alzheimer’s disease biomarkers to physicians across Canada.

Reflecting her group’s research accomplishments, Dr. DeMarco is the recipient of the University of British Columbia’s Early Career Excellence in Research and Discovery, the American Association of Clinical Chemist’s Outstanding Scientific Achievements by a Young Investigator award, and the Association for Mass Spectrometry and Advances in the Clinical Lab’s Michael S. Bereman Award for Innovative Clinical Proteomics.

2021 Manuela Neuman
2020 Robert Hegele
2019 Vathany Kulasingam
2018 Marvin Fritzler
2017 Dan Holmes
2016 George Cembrowski
2015 Loralie Langman
2014 Matthew McQueen
2013 Qing Meng
2012 Reinhold Vieth
2011 Peter A. Kavsak
2010 Bhushan Kapur
2009 Denis Lehotay
2008 Amin Nanji
2007 François Rousseau
2006 Robert Meatherall
2005 Sudesh Vasdev
2004 Jack Gauldie
2003 Edgard Delvin
2002 David E.C. Cole
2001 Jean-Claude Forest
2000 Robert E. Hill
1999 Khosrow Adeli
1998 Choong-Chin Liew
1997 Juri Frohlich
1996 Randell W. Yatscoff
1995 Eleftherios Diamandis
1994 Jawahar Kalra
1993 Steven J. Soldin
1992 A.R. Henderson
1991 Claude PetitClerc
1990 W. Purdy
1989 Henry Friesen (1st recipient)

1. The Award shall be presented to an individual or group, as a mark of recognition of their contribution to research directly or indirectly related to clinical chemistry in Canada.

2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no group or individual is available in any year, the Award shall not be made.

3. Ortho-Clinical Diagnostics have agreed to make an annual contribution of $3,000 CDN. The Award shall be accompanied by a framed certificate and by an honorarium in the amount of $1,500. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.

4. The Awards Committee shall choose the recipient(s) of the Award.

5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting for the year for which the Award is made.

6. The President of the Society will notify the recipient(s) of the award and inform Ortho Clinical Diagnostics of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made. . 7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society. A representative of Ortho-Clinical Diagnostics shall be invited to participate in the presentation.

8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.

9. The amendment of these Terms of Reference is the responsibility of the Council of the Society, subject to the concurrence of the sponsor of the Award. Council of the Society and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

 

Education Excellence

Vathany Kulasingam

Presented to an individual or group as a mark of recognition of outstanding contribution to education in the field of clinical chemistry

Sponsored by:

The Canadian Society of Clinical Chemists is pleased to present the CSCC Award for Education Excellence, sponsored by Beckman Coulter, to Dr. Vathany Kulasingam.

Dr. Vathany Kulasingam is currently the Division Head of Clinical Biochemistry at University Health Network and an Associate Professor and Member of the Graduate Faculty of the Department of Laboratory Medicine and Pathobiology, University of Toronto.

Dr. Kulasingam is the Co-Director of the University of Toronto’s Postdoctoral training program in Clinical Chemistry. Since starting at University Health Network in 2010, Dr. Kulasingam has trained over 27 Clinical Chemistry post-doctoral fellows. She actively leads tutorial sessions on mass spectrometry, tumor markers and point-of-care testing and participates in the program’s journal club discussions. She also leads weekly 3-hr teaching sessions with the first year fellows for 6 months of the year broadly covering areas such as autoimmune diagnostics, proficiency testing and quality control. More recently, she has engaged UHN’s physicians to provide clinical perspective teaching sessions on laboratory test ordering. In her clinical capacity in overseeing the Immunology Laboratory at UHN, Dr. Kulasingam has trained over 25 Hematology residents and myeloma fellows in the area of laboratory testing as it relates to multiple myeloma work-up. She is active in the Hematopathology academic half day pilot program for the province. Dr. Kulasingam has also designed, developed and currently coordinates a graduate course, (LMP1207H: Proteomics, Mass Spectrometry and their Clinical Applications), covering the fundamentals of modern mass spectrometry and its use with biochemical techniques to provide unique analyses of proteins and small molecules, bioinformatics, proteomics, and research and clinical applications of this technology. This course was nominated for the 2021 John B. Walter Prize for Course & Curriculum Design & Development which recognizes outstanding contributions by any member of LMP to the design, development, co-ordination, or administration of any course or curriculum in the Faculty of Medicine. She has also lectured at several different graduate and undergraduate courses at the University of Toronto and at The Michener Institute of Education.

Dr. Kulasingam is a Member of the University of Toronto graduate school and has completed the supervision of two PhD Theses and have been on thesis advisory committees of over 20 students.

Besides actively teaching in all areas of education at the University of Toronto, Dr. Kulasingam is also active in international education – whether this is in the form of invited lectures, creating learning modules for the European Federation of Clinical chemistry and Lab medicine syllabus course or having observership programs for international trained medical residents and clinical chemistry fellows. Besides education, her research interests include using high-throughput “omics” technologies to understand disease pathogenesis, with a particular emphasis on cancer and rheumatic diseases and its application to clinical practice.

See Less

2021 Hossein Sadrzadeh
2020 Fred Apple
2019 Post-doctoral Training Program in Clinical Chemistry, Université de Montréal
2018 Paul Yip
2017 Martha Lyon
2016 Lynn Allen & Edward Randell
2015 Arlene Crowe
2014 A. Mabood Qureshi
2013 Barry Hoffman
2012 Khosrow Adeli
2011 Stephen Hill
2010 Art Vandenbroucke
2009 Gillian Lockitch
2008 Trefor Higgins
2007 John Krahn
2006 Roger Sanfaçon
2005 Donald LeGatt
2004 Christine Collier
2003 Eleftherios Diamandis
2002 Gillian Luxton
2001 Morris Pudek
2000 Education Committee
1999 David M. Goldberg
1998 William E. Schreiber
1997 J.C. Crawhall
1996 Peter Bunting
1995 R. Stinson
1994 Lynn C. Allen
1993 J.T. Hindmarsh
1992 Roger J. Thibert
1991 Marcel Blanchaer
1990 Donald J. Campbell

1. The Award shall be presented to an individual or group, as a mark of recognition of their contribution to research directly or indirectly related to clinical chemistry in Canada.

2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no group or individual is available in any year, the Award shall not be made.

3. Ortho-Clinical Diagnostics have agreed to make an annual contribution of $3,000 CDN. The Award shall be accompanied by a framed certificate and by an honorarium in the amount of $1,500. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.

4. The Awards Committee shall choose the recipient(s) of the Award.

5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting for the year for which the Award is made.

6. The President of the Society will notify the recipient(s) of the award and inform Ortho Clinical Diagnostics of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made. . 7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society. A representative of Ortho-Clinical Diagnostics shall be invited to participate in the presentation.

8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.

9. The amendment of these Terms of Reference is the responsibility of the Council of the Society, subject to the concurrence of the sponsor of the Award. Council of the Society and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

 

CACB Award

Cheryl Tomalty

This award recognizes outstanding contributions by a Fellow of the Academy who advances the standards and recognition of Clinical Biochemistry as a Health Care Profession and thereby advances the professional objectives of the Academy.

Sponsored by:

CACB is pleased and honored to announce that Dr. Cheryl Tomalty will be receiving the 2022 CACB Award for Outstanding Service to the Profession of Clinical Biochemistry. This award recognizes an individual who has made unique and significant contributions to laboratory medicine and has had a global impact on clinical medicine.

Cheryl became interested in a career in Clinical Biochemistry during her first year in the B.Sc. Program at McGill University in 1969. She met a fellow student, Michelle Francoeur, who invited her to a family dinner one day. Michelle’s father, Dr. Marc Francoeur, was a Clinical Chemist at Hôpital St Luc and Cheryl became fascinated by the combination of chemistry, biology, and medical science that Dr. Francoeur described as involved in his work. After obtaining a B.Sc. in Biochemistry in 1974, she was accepted into a PhD in Biochemistry at the University of Ottawa in 1979. That year she was accepted into the Post-doctoral Clinical Chemistry Training Program at the University of Toronto, graduating with a Diploma in 1981. She was then hired as the first Clinical Biochemist at the North York General Hospital. She received her certification in Clinical Biochemistry from the Canadian Society of Clinical Chemists (CSCC) in 1982. In 1984, the Canadian Academy of Clinical Biochemistry (CACB) came into being and she became a Founding Fellow of the CACB.

Cheryl joined Douglass Medical Laboratory (now owned by Dynacare Medical Labs) in Ottawa in 1985 as a Clinical Chemist and was later appointed as Technical Director of Chemistry and Hematology. In 1994, she became the Laboratory Coordinator of the Montreal General Hospital responsible for administration of all the clinical laboratories, and she went on to lead the laboratory integration team of the three hospitals of the McGill University Health Centre. She then returned to Ottawa in 2000 as a Clinical Chemist with Abbott Point of Care, manufacturer of the i-STAT System, located in Ottawa. This position allowed her to connect with users worldwide in the proper usage and in the resolution of issues that arose. Cheryl’s fifth and final position began in 2007 when she joined LifeLabs Burnaby Reference Laboratory in BC in November 2007 as a Clinical Biochemist. She retired on March 4, 2022, after over 40 years in the clinical biochemistry laboratory scene.

Cheryl was particularly focused on service in the clinical laboratories, but she also contributed her time to professional organizations, provincial committees, and teaching. In the early 80’s, Dr. Lynn Allen encouraged her to become a member of the CSCC Maintenance of Competency program, the precursor to the CACB PD program. Member submissions were reviewed and evaluated manually at that time. Cheryl was an Executive Council Member of the Ontario Society of Clinical Chemists (OSCC) from 2001- 2003, Vice-President from 2003-2005, and President of the from 2005-2007. She became a member of the CACB Board in 2011-2014 overseeing the applications for Fellowship and then Chair of the CACB from 2015-2017. From 2008 to 2014, she was one of the Associate Editors of the CSCC News. Cheryl was invited to become a member of the Chemistry and Point of Care Testing Advisory Committee of the BC Diagnostic Accreditation Program (DAP), the agency that oversees the clinical laboratory regulations and accreditation on behalf of the College of Physicians and Surgeons of BC. From 2012-2014, she and other provincial colleagues revamped the accreditation standards for the chemistry and POCT devices in terms of QC requirements, maintenance of competency, critical result reporting, and troubleshooting. Cheryl holds an appointment as Clinical Assistant Professor in the Dept. of Pathology and Laboratory Medicine at UBC. She has taught several topics in clinical biochemistry, including carbohydrate metabolism, hypoglycaemia, immunoprecipitation techniques, and protein analysis methods in the 4th year B.Sc. Medical Laboratory Science program every year since 2009. She is particularly proud of her students, some of whom joined LifeLabs and others who were accepted into medical and dental school programs.

Some of her most satisfying accomplishments are projects that involved methodology and instrumentation changes along with introduction of the Fecal Immunochemical Test (FIT) in BC as part of the implementation of the BC Cancer Colon Screening Program. She was a member of the BC Clinical and Support Services FIT Working Group and the FIT Technical Advisory Group. In the latter group she collaborated with Medical and Laboratory technical experts in enhancing and providing oversight of the provincial FIT Quality Assurance Program. LifeLabs is currently the only provider of FIT testing for the BC Cancer Colon Screening Program.

Cheryl is the co-author of two recent peer-reviewed publications: Clinical Biochemistry 51 (2018) 10-20, which provides recommendations for protein electrophoresis reporting from the CSCC Monoclonal Gammopathy Working Group and a review in Clinical Biochemistry 53 (2018) 156-159, which is a position statement from the CSCC on POCT.

2022

Cheryl Tomalty

2021

Stephen Hill

2020

Edgard Delvin

2019

SM Hossein Sadrzadeh

2018

Nathalie Lepage

2017

Edward Randell

2016

Jawahar (Jay) Kalra

2015

Trefor Higgins

2014

Eleftherios Diamandis

2013

Raymond Lepage

2012

Andrew R. MacRae

2011

Sherry L. Perkins

2010

David Kinniburgh

2009

Connie Prosser

2008

Elizabeth Hooper

2007

Kent C. Dooley

2006

Khosrow Adeli

2005

Edward Young

2004

Bhushan Kapur

2003

James Wesenberg

2002

Randall W. Yatscoff

2001

Lynn Allen

2000

Albert D. Fraser

1999

Robert W. Moore

1998

David W. Seccombe

1997

John Krahn

1996

Jean-Claude Forest

1995

A.W. Luxton

1994

Regis Duffy

1993

Maurice Bernstein (awarded posthumously)

1992

Raymond R. Ogilvie

1991

David M. Goldberg

1990

Cliff K. Harris

1989

Guy Letellier

1988

Roger J. Thibert

1987

Chris W. Walker

1986

Paul Desjardins

1985

Matthew J. McQueen

1984

C. Cousins

1983

M. Francoeur (awarded posthumously)

1982

J. Gilbert Hill

1981

J.E. Logan

1980

A.G. Stewart

1979

Leebert A. Wright

1978

Arlene Crowe

1977

Allan G. Gornall

1976

M.W. Weatherburn

1975

Samuel W. Levy

1974

John C. Nixon

1973

Reuben Schucher

1972

R.H. Pearce

1971

C.J. Porter

1970

D.J. Campbell

1969

S.H. Jackson

1968

David B. Tonks (1st winner)

1. The Award shall be presented as a mark of recognition of outstanding achievement in and/or contribution to the field of clinical chemistry.

2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.

3. Siemens has agreed to make an annual contribution of $3,000 CDN to sponsor this award. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.

4. The Awards Committee shall choose the recipient of the Award.

5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.

6. The President of the Society will notify the recipient(s) of the award and inform Siemens Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made. 7. The recipient of the Award is not usually expected to give an address or give a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society. A representative of Siemens shall be invited to participate in the presentation.

8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.

9. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award. Council of the Society and the corporate sponsor of this award should review these terms of reference a minimum of once every 5 years.

Grants by Member Application

Trainee Elective Visit Grants

Short-term visits (i.e. elective visits) to other laboratories provide trainees in laboratory medicine with a unique opportunity to augment their skill sets.

CSCC provides a limited number of Trainee Elective Visit Grants of up to $2,000 per grant each year in support of this important facet of laboratory medicine training.

*Terms & Application are Placeholder only and are meant for proof of concept*

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.

2. Eligible organizations for this award include:

2.1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.

2.2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.

3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:

3.1. Innovation in strategic planning and implementation of laboratory services based on best practices.

3.2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).

3.3. Innovation in teaching and education.

3.4. Promotion of a positive public image for laboratory medicine.

4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:

4.1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.

4.2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.

4.3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).

5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.

6. Nominations for this award shall be solicited annually in the Newsletter of the Society.

7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.

8. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (plaque and display item) at the CSCC Annual Meeting banquet. The award will be presented by a representative from Roche Diagnostics.

The award will cover airfare, accommodations and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. Photographs and a brief summary of the award will be provided to the hospital or institution for their publication.

9. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.

10. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.

11. The President of the Society will notify the recipient organization of the Award, and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.

12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.

13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five year.

Innovation in Laboratory Medicine

Type of Organization (Check as many as apply)(Required)
Outstanding accomplishment criteria met by this initiative/project:(Required)

References

Applications must be completed by CSCC members:
Name of CSCC Member(Required)
Nominating member: (CSCC member completing application form providing letter of nomination)
In Nominated Organization
Address(Required)
Name of Administrator:
Member of organizations administrative team providing letter of reference
In Nominated Organization
Address(Required)
Confirmation(Required)

 

Leadership and/or Administration

Sponsored by CSCC

*Terms & Application are Placeholder only and are meant for proof of concept*

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.

2. Eligible organizations for this award include:

2.1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.

2.2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.

3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:

3.1. Innovation in strategic planning and implementation of laboratory services based on best practices.

3.2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).

3.3. Innovation in teaching and education.

3.4. Promotion of a positive public image for laboratory medicine.

4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:

4.1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.

4.2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.

4.3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).

5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.

6. Nominations for this award shall be solicited annually in the Newsletter of the Society.

7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.

8. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (plaque and display item) at the CSCC Annual Meeting banquet. The award will be presented by a representative from Roche Diagnostics.

The award will cover airfare, accommodations and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. Photographs and a brief summary of the award will be provided to the hospital or institution for their publication.

9. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.

10. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.

11. The President of the Society will notify the recipient organization of the Award, and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.

12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.

13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five year.

Innovation in Laboratory Medicine

Type of Organization (Check as many as apply)(Required)
Outstanding accomplishment criteria met by this initiative/project:(Required)

References

Applications must be completed by CSCC members:
Name of CSCC Member(Required)
Nominating member: (CSCC member completing application form providing letter of nomination)
In Nominated Organization
Address(Required)
Name of Administrator:
Member of organizations administrative team providing letter of reference
In Nominated Organization
Address(Required)
Confirmation(Required)

Trainee Travel Grants

sponsored by CSCC

*Terms & Application are Placeholder only and are meant for proof of concept*

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.

2. Eligible organizations for this award include:

2.1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.

2.2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.

3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:

3.1. Innovation in strategic planning and implementation of laboratory services based on best practices.

3.2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).

3.3. Innovation in teaching and education.

3.4. Promotion of a positive public image for laboratory medicine.

4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:

4.1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.

4.2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.

4.3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).

5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.

6. Nominations for this award shall be solicited annually in the Newsletter of the Society.

7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.

8. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (plaque and display item) at the CSCC Annual Meeting banquet. The award will be presented by a representative from Roche Diagnostics.

The award will cover airfare, accommodations and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. Photographs and a brief summary of the award will be provided to the hospital or institution for their publication.

9. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.

10. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.

11. The President of the Society will notify the recipient organization of the Award, and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.

12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.

13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five year.

Innovation in Laboratory Medicine

Type of Organization (Check as many as apply)(Required)
Outstanding accomplishment criteria met by this initiative/project:(Required)

References

Applications must be completed by CSCC members:
Name of CSCC Member(Required)
Nominating member: (CSCC member completing application form providing letter of nomination)
In Nominated Organization
Address(Required)
Name of Administrator:
Member of organizations administrative team providing letter of reference
In Nominated Organization
Address(Required)
Confirmation(Required)

Education Excellence

*Terms & Application are Placeholder only and are meant for proof of concept*

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.

2. Eligible organizations for this award include:

2.1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.

2.2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.

3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:

3.1. Innovation in strategic planning and implementation of laboratory services based on best practices.

3.2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).

3.3. Innovation in teaching and education.

3.4. Promotion of a positive public image for laboratory medicine.

4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:

4.1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.

4.2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.

4.3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).

5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.

6. Nominations for this award shall be solicited annually in the Newsletter of the Society.

7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.

8. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (plaque and display item) at the CSCC Annual Meeting banquet. The award will be presented by a representative from Roche Diagnostics.

The award will cover airfare, accommodations and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. Photographs and a brief summary of the award will be provided to the hospital or institution for their publication.

9. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.

10. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.

11. The President of the Society will notify the recipient organization of the Award, and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.

12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.

13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five year.

Innovation in Laboratory Medicine

Type of Organization (Check as many as apply)(Required)
Outstanding accomplishment criteria met by this initiative/project:(Required)

References

Applications must be completed by CSCC members:
Name of CSCC Member(Required)
Nominating member: (CSCC member completing application form providing letter of nomination)
In Nominated Organization
Address(Required)
Name of Administrator:
Member of organizations administrative team providing letter of reference
In Nominated Organization
Address(Required)
Confirmation(Required)

Governance & Bylaws

About Us

Learn more about who
we are and what we do.

Awards & Grants

Archives

Provincial Sections

OSCC

ASCC

Academy

Fellowship, Training & Certification Information is located here.

Accreditation of Training Programs

News & Events

Stay up to date with announcements and event listings

CSCC eNews

CSCC Events

The Lab Report

My Profile

PD Credit Dashboard

Listserv

For Members

Here is where you can renew your membership, submit credits and access member only areas of the website

Careers

Volunteer Opportunities

Directory

Resources

Forms

Surveys